Get the Stockscreener App
0.4301
5.24%
0.0214
After Hours:
.43
-0.000100
-0.02%
Bioxcel Therapeutics Inc Stock (BTAI) Forecast
The Bioxcel Therapeutics Inc (BTAI) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $6.1822, representing a +1,337% increase from the current price of $0.4301. The highest analyst price target is $12.06, and the lowest is $0.3046.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BTAI Price Target
Average 32.35
(+7,422% Upside)
Is Bioxcel Therapeutics Inc (BTAI) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 34.06 | Neutral |
| STOCH(9,6) | 9.8458 | Buy |
| STOCHRSI(14) | 15.47 | Buy |
| MACD(12,26) | -0.0493 | Sell |
| ADX(14) | 21.60 | Neutral |
| William %R | -90.47 | Buy |
| CCI(14) | -78.77 | Neutral |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.5075
Sell
|
0.4933
Sell
|
| MA20 |
0.5785
Sell
|
0.5407
Sell
|
| MA50 |
0.5812
Sell
|
0.6077
Sell
|
| MA100 |
0.7051
Sell
|
0.8301
Sell
|
| MA200 |
1.4916
Sell
|
1.4708
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, BTAI could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 11 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on BTAI, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 34.06 indicates that BTAI is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 9.8458 indicates that BTAI is oversold. This indicates that BTAI price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 15.47 indicates that BTAI is oversold. This suggests that BTAI price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.6 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -78.77 indicates that BTAI is still oversold but not to an extreme extent.
Long-term BTAI price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Bioxcel Therapeutics Inc financial reports and earnings history, Bioxcel Therapeutics Inc (BTAI) stock could reach $6.1184 by 2030, $13.42 by 2040 and $6.4591 by 2050. See the projected annual prices until 2050 of the Bioxcel Therapeutics Inc stock below:
- Bioxcel Therapeutics Inc (BTAI) is expected to reach an average price of $1.2847 in 2035, with a high prediction of $1.1979 and a low estimate of $1.0213. This indicates an $198.70% rise from the last recorded price of $0.4301.
- Bioxcel Therapeutics Inc (BTAI) stock is projected to chart a bullish course in 2040, with an average price target of $10.46, representing an $2,332% surge from its current level. The forecast ranges from a conservative $6.1455 to a sky-high $13.42.
- Our analysts predict Bioxcel Therapeutics Inc (BTAI) to jump 1,171% by 2045, soaring from $4.3727 to an average price of $5.4678, potentially reaching $4.5895. While $4.3727 is the low estimate, the potential upside is significant.
- Bioxcel Therapeutics Inc (BTAI) stock is expected to climb by 2050, reaching an average of $6.8291, a $1,488% jump from its current level. However, a wide range of estimates exists, with high and low targets of $6.4591 and $7.2877, respectively, highlighting the market's uncertainty.
Bioxcel Therapeutics Inc Stock (BTAI) Year by Year Forecast
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2025
Bioxcel Therapeutics Inc Stock (BTAI) is expected to reach an average price of $32.35 in 2025, with a high prediction of $64.40 and a low estimate of $0.3046. This indicates an +7,422% rise from the last recorded price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $8.7504 | $0.3046 | $12.06 | +1,934% |
| February, 2025 | $8.632 | $4.2033 | $10.83 | +1,907% |
| March, 2025 | $27.61 | $8.7849 | $35.96 | +6,320% |
| April, 2025 | $14.14 | $6.1923 | $31.60 | +3,188% |
| May, 2025 | $20.64 | $8.491 | $23.53 | +4,699% |
| June, 2025 | $39.81 | $22.96 | $42.63 | +9,156% |
| July, 2025 | $45.55 | $33.97 | $50.57 | +10,490% |
| August, 2025 | $44.98 | $40.13 | $54.28 | +10,357% |
| September, 2025 | $41.56 | $36.96 | $64.40 | +9,563% |
| October, 2025 | $34.11 | $29.39 | $41.41 | +7,832% |
| November, 2025 | $36.52 | $32.50 | $43.77 | +8,390% |
| December, 2025 | $38.96 | $36.19 | $48.22 | +8,958% |
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2026
The predicted value for Bioxcel Therapeutics Inc (BTAI) in 2026 is set at an average of $39.37. Estimates vary from a peak of $61.38 to a trough of $17.37, indicating an +9,054% surge from the present price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $37.95 | $37.04 | $51.29 | +8,724% |
| February, 2026 | $44.74 | $34.43 | $45.85 | +10,303% |
| March, 2026 | $45.03 | $39.39 | $48.54 | +10,371% |
| April, 2026 | $48.38 | $38.74 | $61.38 | +11,148% |
| May, 2026 | $38.51 | $33.20 | $54.04 | +8,854% |
| June, 2026 | $29.71 | $28.27 | $40.85 | +6,808% |
| July, 2026 | $25.43 | $21.96 | $30.26 | +5,812% |
| August, 2026 | $31.91 | $24.44 | $33.05 | +7,319% |
| September, 2026 | $22.12 | $20.38 | $32.87 | +5,044% |
| October, 2026 | $20.47 | $18.02 | $22.39 | +4,660% |
| November, 2026 | $23.80 | $17.37 | $24.01 | +5,433% |
| December, 2026 | $24.85 | $22.69 | $26.79 | +5,678% |
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Bioxcel Therapeutics Inc (BTAI) is $17.68, with a high forecast of $31.11 and a low forecast of $4.2408. This indicates an +4,010% increase from the last price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $24.38 | $21.11 | $27.69 | +5,569% |
| February, 2027 | $20.06 | $19.25 | $31.11 | +4,565% |
| March, 2027 | $17.06 | $13.47 | $20.92 | +3,866% |
| April, 2027 | $14.35 | $12.86 | $18.03 | +3,236% |
| May, 2027 | $10.60 | $9.216 | $14.15 | +2,365% |
| June, 2027 | $11.65 | $10.31 | $14.64 | +2,608% |
| July, 2027 | $16.06 | $9.5372 | $18.67 | +3,634% |
| August, 2027 | $8.9196 | $8.3796 | $19.76 | +1,974% |
| September, 2027 | $7.6041 | $4.3883 | $10.15 | +1,668% |
| October, 2027 | $5.7758 | $4.2408 | $7.767 | +1,243% |
| November, 2027 | $11.75 | $5.8387 | $12.75 | +2,631% |
| December, 2027 | $11.29 | $9.279 | $13.65 | +2,525% |
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2028
In 2028, Bioxcel Therapeutics Inc (BTAI) is projected to reach an average price of $16.59, with a high projection of $30.46 and a low estimate of $2.7229. This indicates an +3,758% rise from the last price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $9.8135 | $8.9085 | $11.67 | +2,182% |
| February, 2028 | $7.6551 | $6.8151 | $11.19 | +1,680% |
| March, 2028 | $8.5397 | $5.9038 | $9.0497 | +1,886% |
| April, 2028 | $11.65 | $7.2555 | $13.45 | +2,609% |
| May, 2028 | $18.13 | $10.88 | $18.80 | +4,114% |
| June, 2028 | $26.55 | $16.36 | $27.20 | +6,072% |
| July, 2028 | $29.47 | $23.89 | $30.46 | +6,752% |
| August, 2028 | $17.11 | $16.72 | $30.36 | +3,879% |
| September, 2028 | $13.83 | $13.06 | $19.01 | +3,114% |
| October, 2028 | $19.81 | $13.19 | $20.57 | +4,505% |
| November, 2028 | $15.68 | $13.71 | $26.22 | +3,546% |
| December, 2028 | $3.5029 | $2.7229 | $18.85 | +714.45% |
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2029
The 2029 price forecast for Bioxcel Therapeutics Inc Stock (BTAI) is $4.6586 on average, with a high prediction of $9.2887 and a low estimate of $0.0286. This represents an +983.15% increase from the previous price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $6.0975 | $3.6458 | $9.2887 | +1,318% |
| February, 2029 | $1.0691 | $0.7791 | $6.0104 | +148.57% |
| March, 2029 | $0.4807 | $0.3757 | $1.152 | +11.77% |
| April, 2029 | $0.3623 | $0.0286 | $0.9423 | -15.76% |
| May, 2029 | $2.5168 | $0.3298 | $2.6668 | +485.18% |
| June, 2029 | $1.3285 | $0.7297 | $2.9896 | +208.87% |
| July, 2029 | $0.4801 | $0.4301 | $1.4114 | +11.62% |
| August, 2029 | $0.8646 | $0.0487 | $1.2544 | +101.02% |
| September, 2029 | $0.8062 | $0.3534 | $1.8604 | +87.45% |
| October, 2029 | $0.6607 | $0.4079 | $1.2591 | +53.63% |
| November, 2029 | $0.6924 | $0.4566 | $1.0185 | +60.98% |
| December, 2029 | $6.16 | $0.4853 | $5.4873 | +1,332% |
Bioxcel Therapeutics Inc Stock (BTAI) Price Forecast for 2030
Bioxcel Therapeutics Inc Stock (BTAI) is expected to reach an average price of $14.25 in 2030, with a high forecast of $28.29 and a low forecast of $0.2182. This signifies an +3,214% surge from the last price of $0.4301.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $6.111 | $6.471 | $6.1184 | +1,321% |
| February, 2030 | $6.5477 | $6.0135 | $5.9251 | +1,422% |
| March, 2030 | $6.5145 | $6.2803 | $6.1519 | +1,415% |
| April, 2030 | $6.8112 | $7.6512 | $7.7129 | +1,484% |
| May, 2030 | $9.3722 | $6.0338 | $8.5022 | +2,079% |
| June, 2030 | $11.56 | $10.39 | $10.53 | +2,588% |
| July, 2030 | $9.9499 | $10.73 | $11.92 | +2,213% |
| August, 2030 | $7.2367 | $8.8967 | $9.1092 | +1,583% |
| September, 2030 | $1.4852 | $3.6034 | $5.0609 | +245.32% |
| October, 2030 | $22.07 | $0.2182 | $26.13 | +5,030% |
| November, 2030 | $4.8589 | $1.7989 | $28.29 | +1,030% |
| December, 2030 | $2.0821 | $0.8195 | $10.83 | +384.09% |
1.58%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):